Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMVIG for Prevention of Transfusion-Transmitted CMV in Neonates
NCT00000584Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 1983
- Modality
- IgG Antibodies, Antibody Conjugates, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus infection (CMV) comparing CMVIG with Placebo (2 arms). Primary endpoint: Incidence of cytomegalovirus infections at 12 weeks. Started Jul 1983; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00000584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000584.